Interferon Beta-1a in Children with Multiple Sclerosis is Well Tolerated

Waubant, E.; Hietpas, Jack; Stewart, Thomas; Dyme, Z.; Herbert, Joseph; Lacy, Jill; Miller, Carolyn; Rensel, Mary; Schwid, Steven R.; Goodkin, D E

doi:10.1055/s-2001-17370

Cited by 89 publications

(50 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1,3 The European document suggested early use of DMTs to prevent relapses, accumulation of disability, and accumulation of brain damage, recommending careful clinical and MRI follow-up. 3 Similarly, the International Pediatric Multiple Sclerosis Study Group consensus statement Table 1 Demographic and clinical findings of studies a evaluating the results of interferon-b (IFN-b) and glatiramer acetate in pediatric patients with multiple sclerosis Waubant et al 16 Mikaeloff et al 17 Ghezzi et al 21 Pohl et al 19 Tenembaum and Segura 20 Ghezzi et al 21 Tenembaum et al 22 Banwell et al 23 Mikaeloff et al 24 Kornek et al 25 Ghezzi et al 21 Drug The general approach is shown in the figure.…”

Section: Results In Young Children Vs Adolescentsmentioning

confidence: 99%

See 1 more Smart Citation

Pediatric multiple sclerosis

et al. 2016

View full text Add to dashboard Cite

Many disease-modifying therapies are currently available for adults with relapsing-remitting multiple sclerosis (MS) but none of them has been tested in pediatric MS in randomized placebo-controlled trials. At present, as suggested by observational studies and experts' guidelines, interferon-b and glatiramer acetate continue to be the standard first-line treatments for pediatric MS. Observational studies and some controlled unblinded trials have shown a positive effect of these meditations in reducing relapse rate and delaying disease progression, with an acceptable safety profile. The goal of this article is to provide an overview of current knowledge with regard to safety, tolerability, and efficacy of first-line treatment options for MS in the pediatric age group, with the aim of providing guidance for planning first-line treatment of MS in children and adolescents. Neurology ® 2016;87 (Suppl 2):S97-S102 GLOSSARY DMT 5 disease-modifying therapies; GA 5 glatiramer acetate; IFN-b 5 interferon-b; MS 5 multiple sclerosis; NAb 5 neutralizing antibodies; RRMS 5 relapsing-remitting multiple sclerosis.Many disease-modifying therapies (DMT) are currently available for adults with relapsing-remitting multiple sclerosis (RRMS), including interferon-b (IFN-b) 1a/1b, glatiramer acetate (GA), teriflunomide, dimethyl fumarate, natalizumab, fingolimod, and alemtuzumab. Their effectiveness has been demonstrated by phase 3 studies and by observational postmarketing studies for some. [1][2][3][4][5] IFN-b, GA, and teriflunomide have also been tested in patients with clinically isolated syndrome (CIS), and have been found to reduce the risk of a subsequent attack. [6][7][8][9][10] Results are disappointing in the treatment of secondary progressive multiple sclerosis (MS) as only IFN-b was shown to reduce the progression if administered to patients with a residual inflammatory component. 11,12 No medication currently approved for adults with RRMS has completed testing for pediatric MS in randomized placebo-controlled trials, although several pediatric MS trials have recently been launched. Use of DMT in pediatric MS remains off-label in many countries, especially in patients younger than 12 years; nevertheless, these medications are widely used.The high frequency of relapses in pediatric MS, especially in the first years, with a relapse rate higher than that of adults, and the pattern of MRI lesions, with more pronounced inflammatory aspects, support the use of DMT in the pediatric population as they mainly target the inflammatory component. 1,3 Recent volumetric MRI data have demonstrated that pediatric patients with MS have a smaller overall brain volume than would be expected for age, 13 in spite of the purported higher capability to compensate for brain damage, 14 suggesting that demyelinating lesions can also affect overall brain growth and development. It is also important to note that cognitive dysfunction occurs in about 1/3 of children and adolescents with MS. These findings additionally support the view that ped...

show abstract

Section: Results In Young Children Vs Adolescentsmentioning

confidence: 99%

“…[15][16][17][18][19][20][21][22][23][24][25] Data from observational studies are available in about 600 patients treated with IFN-b: 7 studies included .20 patients; 6 have a follow-up of 2 years or more.…”

mentioning

confidence: 99%

Pediatric multiple sclerosis

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Experience in the pediatric population (ages 6 -18) has recently been documented by several groups. [45][46][47][48][49][50] Safety was the primary focus of these studies, and although there are reports of incidental adverse events, adult doses appear to be well tolerated if started on an initial titration schedule. Some doses used in these studies vary empirically, based on the size of the child, ranging from one-third to full adult dose.…”

Section: Pediatric Msmentioning

confidence: 99%

Interferon-β Treatment for Multiple Sclerosis

Bermel

Rudick

2007

Neurotherapeutics

View full text Add to dashboard Cite

Summary:Multiple sclerosis (MS) is the leading nontraumatic cause of neurologic disability in young adults. Interferon-␤, approved for use in 1993, was the first treatment to modify the course and prognosis of the disease and remains a mainstay of MS treatment. Numerous large-scale clinical trials in early, active patient populations have established the clinical efficacy of interferon-␤ in reducing relapses and delaying disability progression. Although its mechanism of action remains incompletely understood, a reduction in active lesions seen on magnetic resonance imaging implies primary anti-inflammatory properties, a mechanism supported by basic immunologic research. Variation in individual patient responsiveness to interferon-␤ may be due to disease variability or differential induction of interferon-stimulated genes. The magnitude of the therapeutic effect appears to be similar among products, but the optimal dose, route, and frequency of administration of the drug remain uncertain.

show abstract

“…By contrast, only few studies on immunomodulatory therapy in childhood MS have been published. These mainly describe the tolerability and side effects of IFNβ-1, which are similar to those observed in adults [16,31,37,60]. In order to evaluate the efficacy of IFNβ-1 in childhood and juvenile MS, phase III clinical trials are warranted.…”

Section: Multiple Sclerosismentioning

confidence: 93%

IVIG therapy in neurological disorders of childhood

Archelos

Fazekas

2006

J Neurol

View full text Add to dashboard Cite

There is growing evidence that intravenous immunoglobulins (IVIG) are effective in some neuroimmunological disorders of childhood. This short review summarizes the evidence-based indications and recommendations of IVIG therapy in these disorders. Despite considerable efforts to define the role and mechanisms of IVIG, more clinical studies are needed to further explore the therapeutic potential of IVIG in childhood diseases of the nervous system and muscle.

show abstract

Interferon Beta-1a in Children with Multiple Sclerosis is Well Tolerated

Abstract: Preliminary data indicate that weekly intramuscular injections of IFNB-1 a are well tolerated.

Cited by 89 publications

References 8 publications

Pediatric multiple sclerosis

Pediatric multiple sclerosis

Interferon-β Treatment for Multiple Sclerosis

IVIG therapy in neurological disorders of childhood

Contact Info

Product

Resources

About